TY  - JOUR
AU  - Fernandez, Oscar
AU  - Giovannoni, Gavin
AU  - Fox, Robert J
AU  - Gold, Ralf
AU  - Phillips, J Theodore
AU  - Potts, James
AU  - Okwuokenye, Macaulay
AU  - Marantz, Jing L
PY  - 2017
DO  - 10.1016/j.clinthera.2017.06.012
UR  - http://hdl.handle.net/10668/11447
T2  - Clinical therapeutics
AB  - In Phase III studies (DEFINE [Determination of the Efficacy and Safety of Oral Fumarate in Relapsing-Remitting MS]/CONFIRM [Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis]), delayed-release dimethyl fumarate (DMF)...
LA  - en
PB  - Elsevier
KW  - clinical
KW  - delayed-release dimethyl fumarate
KW  - interferon beta
KW  - neuroradiological
KW  - relapsing-remitting multiple sclerosis
KW  - safety
KW  - Adolescent
KW  - Adult
KW  - Delayed-Action Preparations
KW  - Dimethyl Fumarate
KW  - Female
KW  - Glatiramer Acetate
KW  - Humans
KW  - Immunosuppressive Agents
KW  - Interferon-beta
KW  - Male
KW  - Middle Aged
KW  - Multiple Sclerosis, Relapsing-Remitting
KW  - Recurrence
KW  - Risk Assessment
KW  - Treatment Outcome
KW  - Young Adult
TI  - Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
TY  - research article
VL  - 39
ER  -